North Shore University Hospital
Manhasset, New York, 11030, United States
Location status: Recruiting
NCT Number: NCT06965452
This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.
Interested in participating?
Request Info18 year–85 year
All sexes
Interventional
Not applicable
Manhasset, New York, 11030, United States
Location status: Recruiting
This is a single site, single-arm study assessing the feasibility, safety, tolerability, and efficacy of trans-arterial embolization for the treatment of facet pain due to facet arthropathy. Osteoarthritis is a common and major cause of pain and disability. Each spinal level contains multiple joints including the intervertebral discs as well as the facet joints. Degeneration of the facet joints or facet arthritis begins early in life and the prevalence grows with increasing age ultimately reaching as high as 100% in people over 60 years of age. Facet arthritis can lead to the development of facetogenic pain. Previous studies have suggested that trans-arterial embolization may be beneficial for pain in the setting of osteoarthritis. Trans-arterial injections have been described in the knee, hip, and shoulder.
Embolization of the dorsal branches of the segmental arteries supplying the bony elements of the spine is a well-established technique employed for preoperative embolization of bony spinal tumors and metastatic disease. Previous studies have clearly demonstrated safety of the techniques with low overall risk. In one large series of 100 embolizations there was only one recorded complication due to the embolization. However, it has not been described for use in the setting of facet arthropathy (OA of the facet joint). The PI for this study has published the results of large series of embolization for spinal tumors without any serious adverse events. Currently the treatment of lumbar spine OA involved medical management, followed by minimally invasive techniques such as intraarticular injection and neurolysis, which are of questionable efficacy, and ultimately possible spinal surgery and fusion in the setting of degenerative disease and structural abnormalities. The purpose of this study is to demonstrate the safety and preliminary efficacy of trans-arterial facet joint embolization using Embozene microparticles in patients with facet arthropathy and lumbar spine OA.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Once consent is obtained the patient will be scheduled for spinal angiography and embolization. The patient will undergo the procedure at North Shore University Hospital. After embolization the patient will be monitored in recovery for 5 hours and then discharged to home.
The primary objective of this study is to examine the safety and feasibility of trans arterial embolization of the facet joint using Embozene Microspheres for the treatment of back pain from facet arthropathy and osteoarthritis.
Time frame: 1 year
The primary outcome measurements for safety are:
-The number of procedure-related serious adverse events occurring in the perioperative period
Time frame: 1 year
Secondary endpoints include:
Time frame: 1 year
Secondary endpoints include:- >20% improvement in disability based on Oswestry Low Back Pain Disability Questionnaire.Percent from 0% to 100% and higher % represents greater improvement.
Contact information is provided by the study sponsor or research team.
Northwell Health
Other
Trans Arterial Embolization for Facet Arthropathy
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07629466
Back Pain, Facet Joint Arthropathy
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT06670404
Facet Joint Arthropathy, Fractures, Bone
Lausanne, Switzerland
View Trial DetailsNCT01298765
Arthritis, Back Pain
Birmingham, Alabama, United States
View Trial DetailsNCT00580294
Arthritis, Arthritis, Rheumatoid
New York, United States
View Trial Details